^
Association details:
Biomarker:HER-2 L755S
Cancer:Gastric Cancer
Drug:CL-387785 (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

Published date:
10/28/2011
Excerpt:
Lapatinib-resistant ERBB2 mutations were found to be highly resistant towards AEE788 treatment but remained sensitive towards the dual irreversible inhibitors CL-387785 and WZ-4002.
DOI:
10.1371/journal.pone.0026760